Las nuevas estrategias para inventar enfermedades

Eduardo Cuestas

doi:10.31053/1853.0605.v68.n3.21507

Autores/as

Eduardo Cuestas Hospital Privado Universitario de Córdoba.

DOI:

https://doi.org/10.31053/1853.0605.v68.n3.21507

Resumen

La percepción de la salud se encuentra cada vez más bombardeada por una serie de mensajes seductores que afirman que al ideal de salud se llega mediante el consumo de fármacos, operaciones u otras intervenciones médicas que producen bienestar aparente.

En las sociedades occidentales contemporáneas, basadas en la maximización de beneficios económicos sobre todas las cosas, es cada vez más frecuente que los pacientes, sean trasmutados a clientes-consumidores, y éstos, en forma paulatina y creciente se hayan ido acostumbrando a comprar, dentro de las posibilidades y coberturas de cada quien, todo aquello que desean, anhelan o entiendan que los hará felices.

Descargas

Los datos de descarga aún no están disponibles.

Referencias

Flower R. Lifestyle drugs: pharmacology and the social agenda. Trends Pharmacol Sci. 2004;25:182–5.

Wolinsky H. Disease mongering and drug marketing. EMBO. 2005;6: 612–4.

Ruiz-Cantero MT. Marketing farmacéutico. Fronterad [Edición electrónica]. 2010.

Ilich I. Némesis médica. México: Ediciones Joaquín Mortiz; 1976.

Payer L. Disease-mongers: how doctors, drug companies, and insurers are making you feel sick. Nueva York: John Wiley & Sons; 1992.

Moynihan R, Henry D. The fight against disease mongering: generating knowledge for action. PLoS Med. 2006;3:e191.

Laboratorios Merck. Financial results. [Edición electrónica]. 20 Enero 2010. Disponible en: http://www.merck.com/newsroom/pdf/4q07 financial results.pdf.

Vlassov VV. Is content of medical journals related to advertisements? Case-control study. Croat Med J. 2007;48:786–90.

Spurling GK, Mansfield PR, Montgomery BD, et al. Information from pharmaceutical companies and the quality, quantity, and cost of physicians’ prescribing: a systematic review. PLoS Med. 2010;7:e1000352.

Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ. 2002;324:886–91.

Moynihan R, Mintzes B. Sex, lies and pharmaceuticals. How drug companies plan to profit from female sexual dysfunction. Canada: Greystone. 2010.

Bramesfeld A, Grobe T, Schwartz FW. Who is treated, and how, for depression? An analysis of statutory health insurance data in Germany. Soc Psychiatry Epidemiol. 2007;42:740–6.

Castiel L, Álvarez-Dardet C. La salud persecutoria. Rev Saúde Pública. 2007;41:461–6.

Alonso-Coello P, García-Franco AL, Guyatt G, et al. Drugs for pre-osteoporosis: prevention or disease mongering? BMJ. 2008;336:126–9.

Dyer O. Disease awareness campaigns turn healthy people into patients. BMJ. 2006;332:871.

Applbaum K. Pharmaceutical marketing and the invention of the medical consumer. PLoS Med. 2006;3:e189.

Fugh-Berman A, Alladin K, Chow J. Advertising in medical journals: should current practices change? PLoS Med. 2006;3:e130.

Chren MM, Landefeld CS. Physicians’ behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA. 1994;271:684–9.

Villanueva P, Peiró S, Librero J, et al. Accuracy of pharmaceutical advertisements in medical journals. Lancet. 2003;361:27–32.

Riera E, De la fuente D, Rodríguez RM. El mensaje publicitario de los anuncios de fármacos en las revistas médicas. Gac Sanit. 2007;21:371–7.

Cooper R, Schriger D. The availability of references and the sponsorship of original research cited in pharmaceutical advertisements. CMAJ. 2005;172:487–91.

Als-Nielson B, Wendong C, Gluud C, et al. Association of funding and conclusions in randomized drug trials. JAMA. 2003;290:921–5.

Kempner J. Gendering the migraine market: do representations of illness matter? Soc Sci Med. 2006;63:1986–97.

Curry P, O’Brien M. The male heart and the female mind: a study in the gendering of antidepressants and cardiovascular drugs in advertisements in Irish medical publication. Soc Sci Med. 2006;62:1970–7.

Ahmed S, Sherry G, Stelfox H, et al. Gender bias in cardiovascular advertisements. J Eval Clin Pract. 2004;10:531–8.

Sufrin CB, Ross JS. Pharmaceutical industry marketing: understanding its impact on women’s health. Obstet Gynecol Surv. 2008;63:585–96.

Appelbaum PS, Gold A. Psychiatrists’ relationships with industry: the principalagent problem. Harv Rev Psychiatry. 2010;18:255–65.

Helmchen H. Psychiatrists and the pharmaceutical industry. Nervenarzt. 2003;74:955–64.

Chilet-Rosell E, Llaguno M, Ruiz-Cantero MT, et al. Hormone replacement therapy advertising: sense and nonsense on the web pages of the best-selling pharmaceuticals in Spain. BMC Public Health. 2010;16:134.

Martín-Llaguno M, Álvarez-Dardet C. La retirada de una campaña publicitaria para promoción de la vacuna tetravalente del virus del papiloma humano en España. Gac Sanit. 2010;24:75–7.

Goldblum OM, Franzblau MJ. Academic medical centers and conflicts of interest. JAMA. 2006;295:2845–6.

Ruiz-Canteroa MT , Cambronero-Saizc B. La metamorfosis de la salud:invención de enfermedades y estrategias de comunicación. Gac Sanit. 2011;25(3):179–181.